The impact of pre-transplant weight loss on survival following cardiac transplantation.


Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
12 2022
Historique:
revised: 07 09 2022
received: 04 08 2022
accepted: 24 09 2022
pubmed: 23 10 2022
medline: 27 12 2022
entrez: 22 10 2022
Statut: ppublish

Résumé

Significant weight loss due to cardiac cachexia is an independent predictor of mortality in many heart failure (HF) clinical trials. The impact of significant weight loss while on the waitlist for heart transplant (HT) has yet to be studied with respect to post-transplant survival. Adult HT recipients from 2010 to 2021 were identified in the UNOS registry. Patients who experienced an absolute weight change from the time of listing to transplant were included and classified into two groups by percent weight loss from time of listing to time of transplant using a cut-off of 10%. The primary endpoint was 1-year survival following HT. 5951 patients were included in the analysis, of whom 763 (13%) experienced ≥10% weight loss from the time of listing to transplant. Weight loss ≥ 10% was associated with reduced 1-year post-transplant survival (86.9% vs. 91.0%, long-rank p = .0003). Additionally, weight loss ≥ 10% was an independent predictor of 1-year mortality in a multivariable model adjusting for significant risk factors (adjusted HR 1.23, 95% CI 1.04-1.46). In secondary analyses, weight loss ≥ 10% was associated with reduced 1-year survival independent of hospitalized status at time of transplant as well as obesity status at listing (i.e., body mass index [BMI] < 30 kg/m Preoperative weight loss ≥ 10% is associated with reduced survival in patients listed for HT. Nutrition interventions prior to transplant may prove beneficial in this population.

Sections du résumé

BACKGROUND
Significant weight loss due to cardiac cachexia is an independent predictor of mortality in many heart failure (HF) clinical trials. The impact of significant weight loss while on the waitlist for heart transplant (HT) has yet to be studied with respect to post-transplant survival.
METHODS
Adult HT recipients from 2010 to 2021 were identified in the UNOS registry. Patients who experienced an absolute weight change from the time of listing to transplant were included and classified into two groups by percent weight loss from time of listing to time of transplant using a cut-off of 10%. The primary endpoint was 1-year survival following HT.
RESULTS
5951 patients were included in the analysis, of whom 763 (13%) experienced ≥10% weight loss from the time of listing to transplant. Weight loss ≥ 10% was associated with reduced 1-year post-transplant survival (86.9% vs. 91.0%, long-rank p = .0003). Additionally, weight loss ≥ 10% was an independent predictor of 1-year mortality in a multivariable model adjusting for significant risk factors (adjusted HR 1.23, 95% CI 1.04-1.46). In secondary analyses, weight loss ≥ 10% was associated with reduced 1-year survival independent of hospitalized status at time of transplant as well as obesity status at listing (i.e., body mass index [BMI] < 30 kg/m
CONCLUSIONS
Preoperative weight loss ≥ 10% is associated with reduced survival in patients listed for HT. Nutrition interventions prior to transplant may prove beneficial in this population.

Identifiants

pubmed: 36271917
doi: 10.1111/ctr.14831
pmc: PMC9984247
mid: NIHMS1874165
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14831

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL148528
Pays : United States

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Clin Res Cardiol. 2022 Apr;111(4):451-459
pubmed: 34757487
ESC Heart Fail. 2021 Dec;8(6):5293-5303
pubmed: 34599855
J Heart Lung Transplant. 2016 Jan;35(1):1-23
pubmed: 26776864
Nat Rev Cardiol. 2017 Jun;14(6):323-341
pubmed: 28436486
Eur J Heart Fail. 2020 Dec;22(12):2314-2326
pubmed: 32949422
Eur Heart J. 2008 Nov;29(21):2641-50
pubmed: 18819960
Curr Heart Fail Rep. 2013 Dec;10(4):307-14
pubmed: 23925442
JACC Heart Fail. 2013 Apr;1(2):93-102
pubmed: 24621833
Eur J Heart Fail. 2015 Apr;17(4):424-33
pubmed: 25704364
Lancet. 2003 Mar 29;361(9363):1077-83
pubmed: 12672310
Clin Transplant. 2019 Jul;33(7):e13621
pubmed: 31152559
Curr Probl Cardiol. 2020 Nov;45(11):100417
pubmed: 31036371
JAMA Netw Open. 2021 Jan 4;4(1):e2033433
pubmed: 33471118
J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):135-142
pubmed: 21966640

Auteurs

Elissa Driggin (E)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Alice Chung (A)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Daniella Concha (D)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Liam Stanton (L)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Veli K Topkara (VK)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Mathew S Maurer (MS)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Justin A Fried (JA)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Farhana Latif (F)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Koji Takeda (K)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Gabriel Sayer (G)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Nir Uriel (N)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Kevin J Clerkin (KJ)

NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Division of Cardiology, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH